You can buy or sell Zoetis and other stocks, options, ETFs, and crypto commission-free!
Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. Read More These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The company provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals. Zoetis was founded in 1952 and is headquartered in Parsippany, NJ.
Parsippany, New Jersey
52 Week High
52 Week Low
Recent Performance: Zoetis (NYSE: ZTS)
Zoetis trades as part of the healthcare sector and is in the drug manufacturers industry. The company CEO is Juan Ramon Alaix. Zoetis Inc is a developer and manufacturer of drugs providing medicines for animal health, and vaccines for livestock and companion animals. Its products are anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. Previous Intraday Trading Performance: The ZTS stock showed a previous change of 0.89% with an open at 97.00 and a close of 97.77. ...
Yahoo FinanceMar 16
Why Is Zoetis (ZTS) Up 3.9% Since Last Earnings Report?
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. It has been about a month since the last earnings report for Zoetis (ZTS). Shares have added about 3.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Zoetis due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnin...
Simply Wall StMar 6
Should You Worry About Zoetis Inc.’s (NYSE:ZTS) CEO Pay Cheque?
In 2012 Juan Alaix was appointed CEO of Zoetis Inc. (NYSE:ZTS). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at other big companies. Next, we’ll consider growth that the business demonstrates. Third, we’ll reflect on the total return to shareholders over three years, as a second measure of business performance. This method should give us information to assess how appropriately the company pays the CEO. Check out our latest analysis for Zoetis How Does Juan...
Expected May 2, Pre-Market